Selective resection of the medial wall of the cavernous sinus in pituitary surgery: results of a prospective single center analysis.

Purpose: Pituitary adenomas, despite their histologically benign nature, can severely impact patients' quality of life due to hormone hypersecretion. Invasion of the medial wall of the cavernous sinus (MWCS) by these tumors complicates surgical outcomes, lowering biochemical remission rates and increasing recurrence. This study aims to share our institutional experience with the selective resection of the MWCS in endoscopic pituitary surgery.

A Miniaturized Wireless, Battery-free Implant for In Vivo Musculoskeletal Stimulation.

We developed a miniaturized (8 × 8 mm) wireless and battery-free implant for musculoskeletal stimulation. The implant generates an monophasic voltage of up to 11.9 V in a benchtop test with an air link, and it can produce any desired stimulation protocol by responding to the reception of a 2.

Awake Minimally Invasive Surgery Transforaminal Lumbar Interbody Fusion Under Spinal Anesthesia: Screw Placement Accuracy and 1 Year Follow-Up.

Objective: We assessed the accuracy of pedicle screws placed during awake minimally invasive surgery (MIS) transforaminal lumbar interbody fusion (TLIF) under spinal anesthesia and analyzed outcomes at the 1-year follow-up.

Methods: We included patients who underwent awake MIS-TLIF under spinal anesthesia at an academic center from February 2020 to February 2022. The Gertzbein-Robbins classification was used for screw accuracy rating.

Therapeutic potential and impact of nanoengineered patient-derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma.

Confounding results of engineered mesenchymal stem cells (MSCs) used as cellular vehicles has plagued technologies whereby success or failure of novel approaches may be dismissed or inaccurately ascribed solely to the biotechnology platform rather than suitability of the human donor. Polymeric materials were screened for non-viral engineering of MSCs from multiple human donors to deliver bone morphogenic protein-4 (BMP4), a protein previously investigated in clinical trials for glioblastoma (GBM) to combat a subpopulation of highly invasive and tumorigenic clones. A "smart technology" that target the migratory and stem-like nature of GBM will require: (1) a cellular vehicle (MSC) which can scavenge and target residual cells left behind after surgical debulking and deliver; (2) anti-glioma cargo (BMP4).